3 active not recruiting, 2 completed, 2 recruiting, 2 withdrawn. 6 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 2, Withdrawn 2, Completed 1, Recruiting 1 |
| Phase 2 | 5 | Active not recruiting 1, Completed 1, Recruiting 1, Suspended 1, Terminated 1 |
Follow Recurrent Grade 3a Follicular Lymphoma: new trials by email Literature Review of Recurrent Grade 3a Follicular Lymphoma trials Research Report on Recurrent Grade 3a Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 37 | 2025-08-25 | 2026-04-20 |
| Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Suspended | City of Hope Medical Center | 33 | 2025-03-11 | 2026-01-21 |
| Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 41 | 2024-09-09 | 2026-09-22 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2021-07-27 | 2024-04-25 | |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2021-04-01 | 2024-09-19 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat - Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL | Phase 1 | Active not recruiting | City of Hope Medical Center | 52 | 2017-07-18 | 2026-08-21 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma Blinatumomab, Lenalidomide - Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2016-11-15 | 2025-11-26 |
| Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma Anti-ICOS Monoclonal Antibody MEDI-570, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 21 | 2016-09-13 | 2026-06-26 |
| Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Pembrolizumab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 53 | 2015-07-31 | 2026-10-22 |
Lymphoma, Follicular (11) · Lymphoma, B-Cell, Marginal Zone (6) · Lymphoma, Large B-Cell, Diffuse (6) · Lymphoma, Mantle-Cell (6) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, B-Cell (4) · Lymphoma, Non-Hodgkin (2) · Burkitt Lymphoma (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Multiple Myeloma (1) · Mycosis Fungoides (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoma (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Lymphoma, Non-Hodgkin (9) · Hematologic Diseases (6) · Chronic Disease (5) · Disease Attributes (5) · Leukemia (5) · Leukemia, B-Cell (5) · Leukemia, Lymphoid (5)
Lenalidomide (3) · Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · Biopsy (2) · CT-P10 (2) · Rituximab (2) · pembrolizumab (2) · polatuzumab vedotin (2) · CPG-oligonucleotide (1) · Hyaluronoglucosaminidase (1) · LFB-R603 (1) · MEDI-570 (1) · N,N-dicyclohexyl-isoborneol-10-sulfonamide (1) · Nivolumab (1) · Radiation (1)
City of Hope Medical Center (5) · National Cancer Institute (NCI) (2) · Academic and Community Cancer Research United (1) · M.D. Anderson Cancer Center (1) · University of Washington (1) · Yazeed Sawalha (1)
United States (9) · Canada (1)
Alex F Herrera (1) · Catherine S Diefenbach (1) · Geoffrey Shouse (1) · Joseph M Tuscano (1) · Julio C Chavez (1) · Lihua E Budde (1) · Matthew Mei, MD (1) · Rahul Banerjee, MD (1) · Ranjit Nair (1) · Swetha Kambhampati (1) · Yazeed Sawalha, MD (1)
PMID 35015819, PMID 36826995, PMID 37339586, PMID 37470137
P30CA033572 (4), UM1CA186644 (2), P30CA015083 (1), P50CA107399 (1), UM1CA186717 (1)